Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma

NCT03778073 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT03778073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03778073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 17, 2019
Completion date
August 1, 2022
Enrollment
18 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin lymphoma, richter's transformation